Michael Cecchini

21PUBLICATIONS
177CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular targetsPredictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|May 01, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

|Apr 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings.

|Mar 23, 2026
The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.

Michael Cecchini, Sae-Won Han, Soohyeon Lee

|Mar 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial.

Deborah B Doroshow, Geoffrey I Shapiro, Khanh Do

|Feb 19, 2026
PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma.

Princy Gupta, Rushabh Gujarathi, Lu Qiao

|Jan 09, 2026
Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence-Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials.

Guannan Gong, Jessica Liu, Sameer Pandya

Pageof 4

Frequent Collaborators

2 joint publications

Patricia LoRusso

2 joint publications

Lajos Pusztai

2 joint publications

Judit Börcsök

2 joint publications

Pranshu Sahgal